CNN provides an analysis of the stock quote, current price, and future forecast for MRK (Merck & Co.). This report offers insights into the company's market performance.

An analysis explores whether pharmaceutical giant Merck & Co. (MRK) is a favorable investment choice during a bear market, evaluating its resilience and potential for growth.

Merck's proposed acquisition of Terns Therapeutics has successfully passed the expiration of the Hart-Scott-Rodino (HSR) antitrust waiting period, moving the deal closer to completion.

Pharmaceutical companies Merck and Eisai have encountered a setback in a late-stage clinical trial for their Keytruda regimen, intended for the treatment of kidney cancer.

Pfizer and Astellas have received FDA priority review for their bladder cancer treatment, Padcev, when used in combination with Merck's Keytruda, signaling a potential expedited approval process for the therapy.

An article compares Novartis and Merck to determine which pharmaceutical company offers a better dividend stock option for investors.

An analysis suggests a bullish diagonal trade for Merck (MRK) stock, targeting a price of $130 by June 18.

A joint investigation by DW and ICIJ highlights how pricing and patent strategies have made Merck's Keytruda a top-selling drug while limiting access for many patients worldwide. The report uncovers a significant global divide in the availability of the life-saving medicine.

An earnings preview for Merck & Co.'s upcoming quarterly report has been released, offering insights into what investors can expect from the pharmaceutical giant.

This article analyzes whether defensive stocks like Costco and Merck are currently overbought, prompting investors to consider if it's too late to buy them.

Merck & Co. (MRK) is being highlighted as a top affordable stock choice, praised for its robust earnings growth potential.

Merck's oral PCSK9 enlicitide has shown improved cholesterol-lowering capabilities when compared to non-statin treatments.

Merck Life Science has inaugurated an AI-powered chemistry lab at KAIST, strengthening its partnership with Korea’s leading science and technology university.

Merck, the pharmaceutical giant, continues to view China as a crucial and vital base within its global business operations and strategy, reaffirming its commitment to the country.

Pharmaceutical giant Merck has reached an agreement for a deal valued at nearly $6 billion to acquire Terns, a biotechnology company focused on cancer research.

Citi has increased its price target for Merck & Co. (MRK) to $125 from $120.

Merck has reached an agreement to acquire cancer biotech firm Terns in a deal valued at nearly $6 billion, expanding its portfolio in the oncology sector.

An investment analysis evaluating whether Merck & Co., Inc. (MRK) is a good stock to buy now.

Analysts predict Merck's stock (MRK) could reach $150, driven by the potential of its Sac-TMT drug.

Tempus AI, Inc. has announced a strategic deal with Merck to accelerate AI-driven precision medicine initiatives.

German pharmaceutical company Merck announced a 6% drop in profit for 2025, attributing it to geopolitical challenges and exchange rate pressures, but anticipates improved profits in 2026.

Merck is planning to lay off 154 employees, a move that could be part of broader restructuring efforts or a response to changing business needs.

Barclays has started its coverage of Merck (MRK), drawing attention to the company's promising pipeline catalysts as key drivers for future growth.

Merck is restructuring its business by separating its oncology division from non-cancer drug operations, a move reportedly in preparation for the 2028 patent expiry of its blockbuster cancer treatment, Keytruda.

Deutsche Bank has upgraded Merck (MRK) to a 'Buy' rating, expressing optimism about the company's future beyond the patent expiration of its key drug, Keytruda.

Merck & Co. saw its stock advance, driven by robust sales of its drug Keytruda and favorable results from recent clinical trials.

After five years at the helm of Merck, Belén Garijo is stepping down to take on the role of CEO at the French pharmaceutical company Sanofi. This move marks a significant career change for Garijo, who will be taking on a challenging new leadership position.

Belén Garijo, the CEO of Merck, is stepping down from her position, having been the first woman to reach the top leadership role in a DAX-listed company.

Infinimmune and Merck (MRK) have entered into an agreement focused on antibody discovery.

Merck (MRK) is highlighted as one of the top counter-cyclical stocks available for purchase. The analysis details why the pharmaceutical company's stock is considered a strong investment choice, particularly in uncertain economic times.

Pharmaceutical giant Merck and other rival companies are reportedly showing interest in acquiring Inhibrx's cancer drug, signaling potential major developments in the oncology market.

Pharmaceutical manufacturers are facing a potential helium shortage, with current supplies lasting only four to eight weeks, due to disruptions related to the Strait of Hormuz. While Merck does not anticipate immediate bottlenecks, Boehringer is seeking to reduce its reliance on helium imports.

Merck has significantly impacted the funding landscape for vaginal drug delivery, addressing a previous lack of investment in the area.

UBS has increased its price forecast for Merck (MRK) as part of its broader sector preview, indicating a positive outlook for the pharmaceutical giant.

Nevena Vidaković, General Manager and Executive Director of Merck Bulgaria, discusses the factors shaping the future of family-oriented work environments. She shares insights from her extensive career and international experience.

Concerns are rising in India over the cancer drug Keytruda's availability, high cost, and reports of leaks and fake versions. Merck & Co has stated that healthcare facilities are responsible for the used packaging of the drug.

Merck & Co. (MRK) is being evaluated as one of the best consistent dividend stocks available for purchase. This assessment focuses on its reliability for income-seeking investors.

Infinimmune and Merck have entered into a new collaboration agreement focused on antibody discovery. This pact aims to advance research and development in the field of immunology.

Merck Pill Lowers Cholesterol by 64% in Study, Rivaling Shots  Bloomberg.com

This article highlights notable healthcare headlines for the week, focusing on developments related to companies such as Merck, Medtronic, and Novartis.

Jim Cramer suggests that Merck & Co. is likely to be an outperformer if the economy enters a slowdown triggered by an oil shock.

Merck has announced a $6.7 billion deal to acquire a leukemia treatment, a strategic move as the company prepares for the upcoming expiration of exclusivity for its blockbuster cancer drug, Keytruda.

Merck has finalized a deal worth nearly $6 billion to acquire Terns, a cancer biotech company, signaling a major acquisition in the pharmaceutical and biotechnology sector.

Merck is looking to forge deeper collaborations within China's pharmaceutical innovation sector, aiming to expand its presence and contributions to the market.

Merck & Co. (MRK) is implementing measures to mitigate the impact of the upcoming loss of exclusivity for its drug KEYTRUDA.

Leerink has increased its price target for Merck & Co. Inc. (MRK), citing potential upside from the company's cancer drug portfolio.

Pharmaceutical stocks like Eli Lilly and Merck are good places to help investors ride out a recent rise in geopolitical turmoil, according to UBS.

Tuniu has announced its fourth-quarter financial results and introduced its outlook for the first quarter.

Merck plans to lay off approximately 150 employees at a US site due to a slump in sales of its Gardasil vaccine.

RBC Capital projects that Merck (MRK) will return to growth sooner than market expectations.

Pharmaceutical giant Merck is set to establish a distinct cancer unit as the company prepares for an impending patent cliff.

Merck announced plans to divide its human health business into two separate divisions, separating its cancer franchise from non-oncology medicines, to mitigate the impact of Keytruda patent loss.

Analysts are providing their perspectives on the future trajectory of Merck & Co., Inc. (MRK), assessing its potential performance.

The increasing complexity of chips, driven by artificial intelligence, is expected to lead to a significant surge in the semiconductor materials market.

Merck & Co. Inc. is highlighted as one of the top low-risk, high-growth stocks for investors to consider buying at the moment.

Jim Cramer expressed his strong approval for Merck, calling the pharmaceutical company "Terrific."

A financial analysis article examines Wall Street's recommendation to buy Merck over Pfizer, delving into the underlying numbers to present a more nuanced perspective on their stock performance.

Merck & Co., Inc. (MRK) has been granted FDA Priority Review for its KEYTRUDA regimen in the treatment of muscle-invasive bladder cancer.

Pharmaceutical company Merck has secured approval for its new HIV drug regimen, Idvynso, marking a significant development in HIV treatment options.

The Merck Foundation and Kenya's First Lady launched their 'Educating Linda' program at Kenya State House, aimed at supporting girl education.

A recent Merck Youth Barometer survey indicates that 16-20 year olds, particularly young men, favor traditional gender roles where men work and women care for children, while young women advocate for equal roles.

Merck's stock experienced gains, breaking a six-day period of losses in the market.

Pharmaceutical giant Merck is undergoing a transformation driven by strategic acquisitions as it prepares for the upcoming patent expiration of its top-selling cancer drug, Keytruda.

Pharmaceutical giant Merck's stock is reportedly forming a bullish chart pattern, indicating a potential for a significant price jump within the health-care sector.

Pharmaceutical giant Merck & Co (MRK) announced strong financial results for its fourth quarter, leading to a positive market reaction.

Merck (MRK) has announced strong Phase 3 clinical trial results for its oral PCSK9 inhibitor, a drug designed to lower cholesterol.

A late-stage trial of a new Merck drug demonstrated a reduction in bad cholesterol by up to 64.6%, meeting its main goal in a head-to-head trial.

Merck (MRK) shares have risen considerably following financial commentator Jim Cramer's advice to investors to 'stay the course' with the company.

Pharmaceutical giant Merck & Co. has announced its intention to acquire Terns Pharma for $6.7 billion, touting the 'best-in-class' potential of TERN-701 for Chronic Myeloid Leukemia (CML) as a key driver for the deal.

RBC Capital Markets has reiterated its 'Outperform' rating for Merck (MRK), acknowledging investor concerns regarding a 'modest premium' but maintaining a positive outlook for the pharmaceutical company.

Merck has finalized its acquisition of Terns Pharmaceuticals for nearly $6 billion to boost its cancer drug pipeline, though analysts and investors are now questioning the premium paid for the deal.

Pharmaceutical giant Merck has reached an agreement to acquire cancer biotech company Terns in a deal valued at nearly $6 billion, expanding its portfolio in oncology.

Slovenian cycling champion Tadej Pogačar delivered an exceptional performance to secure his maiden victory in the first monument of the season, earning praise from Eddy Merckx.

Merck (MRK) saw a significant surge in its stock performance during the fourth quarter, driven by undisclosed factors.

MSD (known as Merck & Co., Inc. in the US and Canada) today announces the arrival in Greece of a new innovative pneumococcal conjugate vaccine for adults.

Berlusconi bekommt mehr Macht denn je +++ USA verlängern Ausnahme von Sanktionen für Rosneft Deutschland +++ Google eröffnet KI-Zentrum in Berlin +++ Merck erwartet für 2026 einen Gewinnrückgang +++…

Merck has announced a collaboration with Tempus AI to advance precision oncology initiatives, focusing on leveraging AI for cancer treatment and research.

Merck's cancer drug Keytruda has demonstrated an overall survival benefit in patients with ovarian cancer, according to new findings.

An article compares the stock performance of Merck & Co. against other companies in the healthcare sector.

Merck announced positive results from its phase 3 second-season RSV data for the vaccine ENFLONSIA, indicating continued efficacy.